DR-10627

N/A

Report date: 2024/12/30 10:32:34
NME

Base Information

Drug NameDR-10627
Drug Alias NameHZ-010DR-10627
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide Receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes MellitusMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Heze Pharmaceutical Technology Co LtdZhejiang Doer Biologics Corp
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesZhejiang Doer Biologics CorpZhejiang Better Pharmaceuticals Co LtdHangzhou Heze Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes MellitusMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A